One immune-cell marker. A disease with no treatment. And a very expensive bet that the two can be connected.
The Abcuro wordmark - quietly confident, like a company that would rather you read the trial data than the logo.
Walk into Abcuro's offices in Newton, Massachusetts and you would not guess that this is a company carrying $200 million in fresh capital and the hopes of roughly 50,000 patients. Forty-three people. One lead drug. One target. That is the whole operation.
Abcuro is a clinical-stage biotechnology company, which is the polite industry term for "we have not sold anything yet, and we might not for years." What it has instead is conviction - a precise, almost stubborn focus on a single immune-cell receptor called KLRG1, and the belief that learning to find it could change how we treat autoimmune disease and certain cancers. The company spends its days trying to teach an antibody to do one thing extremely well: hunt down the specific T cells that have turned against the body, and leave the rest of the immune system alone.
Most immune drugs are a sledgehammer. Abcuro is trying to build a scalpel.
Inclusion body myositis - IBM, if you are in a hurry - is one of the most common muscle diseases in people over 50. It is also one of the cruelest in its ordinariness. It does not announce itself. It just slowly removes things: grip, then the ability to climb stairs, then the ability to walk. The immune system, which is supposed to be the home team, sends cytotoxic T cells to attack muscle fibers as if they were intruders.
Here is the part that should bother you: there is no approved treatment. None. Decades of work, and the standard of care for IBM is essentially supportive - physical therapy and patience. The broad immunosuppressants that work elsewhere in autoimmune medicine mostly shrug at IBM, because they were never designed to target the specific cells doing the damage.
You cannot fix a problem you cannot find. For years, nobody could find the cells driving IBM.
In 2019, Steven Greenberg - a neurologist at Brigham and Women's Hospital and a professor at Harvard Medical School - co-authored research pointing to a culprit. The most aggressive, tissue-destroying T cells in IBM, it turned out, shared a marker on their surface: KLRG1. It was the molecular equivalent of finding that all the suspects wore the same jacket.
Greenberg became a scientific co-founder of Abcuro, which had been founded in 2015 by Stefano Gulla. The bet was simple to state and brutally hard to execute: build an antibody that recognizes KLRG1, use it to delete the dangerous cells, and spare everything else. If it worked in IBM, the same logic might extend to T-cell cancers, where those same cytotoxic cells turn malignant.
The suspects all wore the same jacket. Abcuro decided to build something that only goes after the jacket.
Investors, it turns out, like a clean hypothesis. The kind of people who write large checks into biotech - NEA, Bain Capital Life Sciences, Sanofi Ventures, BlackRock - tend to be allergic to vague stories. Abcuro had the opposite: a named target, a named drug, and a named disease with a wide-open market.
Ulviprubart - internal name ABC008 - is a first-in-class monoclonal antibody. "First-in-class" means there is nothing else like it, which is exciting and terrifying in roughly equal measure: no one has gone first, so there is no map. It is engineered to bind KLRG1 and selectively deplete the highly cytotoxic T and NK cells that carry it.
Humanized anti-KLRG1 monoclonal antibody designed to delete disease-driving cytotoxic cells without broad immune suppression.
The lead autoimmune indication - a progressive muscle-wasting disease with no approved therapy and FDA orphan drug designation.
T-cell large granular lymphocytic leukemia - applying the same KLRG1 depletion logic to a blood cancer.
Earlier-stage oncology work extending the platform to additional T and NK cell malignancies.
One mechanism, pointed at both autoimmune disease and cancer. That is unusual, and it is the whole appeal: the same cells that wreck muscle in IBM are, in another context, the cells that turn into lymphoma.
A decade compressed into five dots. The hard part - the science - lives in the white space between them.
The clearest evidence that serious people take Abcuro seriously is the cap table. The February 2025 Series C was led by New Enterprise Associates, with Foresite Capital joining and a long list of returning investors: RA Capital, Bain Capital Life Sciences, Redmile, Samsara BioCapital, Sanofi Ventures, Pontifax, Mass General Brigham Ventures, abrdn, BlackRock, Eurofarma Ventures, and Soleus Capital.
Reported financing rounds. The last bar is the one that bought a registrational trial.
Rare disease used to scare investors off. Abcuro's $200M round is a sign that a clean target can still draw a crowd.
Capital is a vote, not a verdict. In March 2026, Abcuro presented data from its registrational Phase II/III MUSCLE study, and the headline was hard: the trial did not hit its primary endpoints. The company pointed to slowing of disease progression in a lower-dose group and in pre-specified patient subsets - threads worth pulling, but not the clean win the field had hoped for. First-in-class means going first, and going first means sometimes the map you draw includes a wall.
Abcuro's stated mission is precise targeting of highly cytotoxic T cells in autoimmune disease. Strip out the jargon and it is a philosophical position about medicine: stop carpet-bombing the immune system to treat a problem caused by a handful of cells. Find the few. Spare the rest.
Those four numbers are the whole tension. A large unmet need, no competition because nothing works yet, a war chest, and a deliberately small team. It is a high-variance setup - the kind that either reshapes a field or becomes a cautionary slide in someone's lecture.
If KLRG1 depletion holds up - if not in this trial then in the subsets, the next dose, the next indication - the implications run past IBM. The same approach is aimed at T-LGLL and T/NK cell lymphomas. A target that matters in both autoimmune disease and cancer is rare, and it is exactly the kind of platform that justifies patience and a big balance sheet.
A drug that fails its first trial is not the same as a wrong idea. Abcuro is finding out which one it has.
Back to that quiet office in Newton. Forty-three people, a marker called KLRG1, and a disease that still, for now, has no treatment. The MUSCLE trial did not close the case. But it did something Abcuro has done since 2015 - it generated data on a problem most of the industry walked past. The patients living with IBM are still waiting. So is the bet. The company that set out to build a scalpel is now studying, very carefully, exactly where it cut.
Note: clinical and financial figures above are drawn from public reporting and company statements. Trial outcomes and pipeline status evolve - treat specific data points as approximate and verify against primary sources before relying on them.